The negative ANSA-RAD trial, when contrasted with the positive STAMPEDE trial, demonstrates that patient selection is paramount in adjuvant therapy. The difference in outcomes was driven by risk definition, not the drug. This reinforces that "negative" trials are clinically vital for defining which patient populations do not benefit, preventing widespread overtreatment.

The CREST trial showed benefit driven by patients with carcinoma in situ (CIS), while the Potomac trial showed a lack of benefit in the same subgroup. This stark inconsistency demonstrates that subgroup analyses, even for stratified factors, can be unreliable and are a weak basis for regulatory decisions or label restrictions.

The ASPIRE trial design was altered due to pushback from patient advocates who felt it was unethical to randomize metachronous low-volume disease patients to a chemotherapy arm. This led to the exclusion of that subgroup, demonstrating how advocate consensus can override a purely biology-based trial design in favor of perceived patient benefit.

The practice-changing KEYNOTE-689 trial was open-label, meaning patients knew their treatment. This could introduce bias; patients on the standard care arm may have dropped out ("bailed"), while those on the pembrolizumab arm might have progressed, artificially making the rates of patients reaching surgery appear similar.

As an open-label trial, investigators' knowledge of treatment arms could introduce bias. Clinicians might give treated patients the "benefit of the doubt" on scans, artificially improving Disease-Free Survival (DFS). This potential bias, which wouldn't affect the harder endpoint of Overall Survival (OS), offers a plausible explanation for the discordance between the two.

The SUNRISE 2 trial's chemoradiation arm showed unexpectedly strong results. This is likely due to a protocol requiring a repeat resection (RIT-URBT) before randomization, which weeded out aggressive tumors and selected a patient population with a better prognosis, making the control arm unusually difficult to beat.

The impressive 68% pathological complete response (pCR) in the SAKK neoadjuvant bladder cancer study may be misleading. Such high rates in single-arm trials are often driven by patient selection biases, such as enrolling patients with earlier T2 disease and those who've had thorough initial surgeries.

Even when trials like LITESPARK 022 and Keynote 564 use identical eligibility criteria, outdated staging systems result in patient populations with different underlying risks. This makes direct comparison of outcomes between trials, even for the same drug, an unfair and statistically flawed analysis that ignores the function of a control arm.

Clinical trials for acute leukemia targeting older or chemotherapy-ineligible patients are enrolling a surprisingly high number of younger individuals. This trend blurs the lines of the intended patient population and affects how trial data should be interpreted and generalized to real-world practice.